Relmada Therapeutics (RLMD) Shares Outstanding (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Shares Outstanding data on file, last reported at $104.9 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $104.9 million, up 216.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $104.9 million (up 216.01% YoY), and the FY2025 annual result was $73.3 million, up 143.03% from the prior year.
• Shares Outstanding grew to $104.9 million in Q1 2026 per RLMD's latest filing, from $73.3 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $104.9 million in Q1 2026 and troughed at $28.6 million in Q3 2022.
• A 5-year average of $37.5 million and a median of $30.2 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding changed 0.0% in 2023, then surged 216.01% in 2026.
• A 5-year view of Shares Outstanding shows it stood at $30.1 million in 2022, then changed by 0.0% to $30.1 million in 2023, then increased by 0.25% to $30.2 million in 2024, then surged by 143.03% to $73.3 million in 2025, then jumped by 43.03% to $104.9 million in 2026.
• Business Quant data shows RLMD's Shares Outstanding at $104.9 million in Q1 2026, $73.3 million in Q4 2025, and $33.2 million in Q3 2025.